Comparative Effectiveness of Tirzepatide vs. Semaglutide for Weight Reduction in Obese Adults
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 22nd, 2024
|
Semaglutide and tirzepatide are two medications widely prescribed for managing type 2 diabetes. Semaglutide works by activating GLP-1 receptors, while tirzepatide targets both GLP-1 and GIP receptors. Both medications help lower cellular glucose absorption and have recently shown potential for weight management. Therefore, a study was conducted to compare the effectiveness of semaglutide and tirzepatide in promoting weight loss.
The retrospective cohort study utilized electronic health records from institutions across the United States, analyzing data from 41,222 obese adults with an average body mass index (BMI) of 39.1. Of these, 32,029 participants were treated with semaglutide, while the remainder received tirzepatide. The median age was 52, with a majority identifying as White. Additionally, 52% of the cohort had type 2 diabetes, and 4.1% had undergone bariatric surgery. After one year, BMI assessments showed that participants on tirzepatide were twice as likely to achieve a 15% weight reduction compared to those on semaglutide. This greater effectiveness was consistent for both individuals with and without type 2 diabetes. The study also found no significant difference in adverse events between the two groups.
The retrospective cohort study utilized electronic health records from institutions across the United States, analyzing data from 41,222 obese adults with an average body mass index (BMI) of 39.1. Of these, 32,029 participants were treated with semaglutide, while the remainder received tirzepatide. The median age was 52, with a majority identifying as White. Additionally, 52% of the cohort had type 2 diabetes, and 4.1% had undergone bariatric surgery. After one year, BMI assessments showed that participants on tirzepatide were twice as likely to achieve a 15% weight reduction compared to those on semaglutide. This greater effectiveness was consistent for both individuals with and without type 2 diabetes. The study also found no significant difference in adverse events between the two groups.